Findings demonstrate improved quality of life in chemotherapy patients with effective antiemetic therapy, highlighting the need for better prophylaxis and patient education.
Summary Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor antagonists has significantly improved control rates, although underutilization of guideline-based prophylaxis persists. Current recommendations emphasize tailoring therapy to the emetogenic potential of agents, with olanzapine now incorporated for improved delayed-phase control. Challenges remain in breakthrough and delayed CINV, steroid-sparing regimens, and individualized risk-adapted prophylaxis. Optimizing adherence to ASCO, NCCN, and MASCC/ESMO guidelines and patient education are key to enhancing outcomes and quality of life during chemotherapy.
No takes yet. Share an insight, caveat, or question.
Georg Jeryczynski (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: